US Stock MarketDetailed Quotes
ENTA Enanta Pharmaceuticals
- 14.680
- +0.360+2.51%
Close Jul 22 16:00 ET
310.91MMarket Cap-2348P/E (TTM)
14.730High14.140Low112.84KVolume14.440Open14.320Pre Close1.65MTurnover0.73%Turnover RatioLossP/E (Static)21.18MShares20.04052wk High1.87P/B226.34MFloat Cap8.08052wk Low--Dividend TTM15.42MShs Float127.770Historical High--Div YieldTTM4.12%Amplitude8.080Historical Low14.621Avg Price1Lot Size
Enanta Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | (Q3)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -4.16%17.05M | -23.67%18M | -8.07%79.2M | -6.82%18.93M | -3.01%18.89M | -4.92%17.8M | -14.70%23.59M | -11.24%86.16M | -13.82%20.32M | -9.92%19.48M |
| Operating revenue | -4.16%17.05M | -23.67%18M | -8.07%79.2M | -6.82%18.93M | -3.01%18.89M | -4.92%17.8M | -14.70%23.59M | -11.24%86.16M | -13.82%20.32M | -9.92%19.48M |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -12.97%49.82M | -1.32%52.89M | 3.05%216.41M | 5.48%49.96M | 6.89%55.61M | 8.91%57.25M | -7.68%53.6M | 1.62%210M | -17.34%47.37M | -6.22%52.02M |
| Selling and administrative expenses | 3.32%14.24M | 30.10%16.52M | 16.28%52.89M | 9.75%13.8M | -2.41%12.62M | 31.52%13.78M | 33.53%12.7M | 39.79%45.48M | 50.42%12.57M | 52.52%12.93M |
| -General and administrative expense | 3.32%14.24M | 30.10%16.52M | 16.28%52.89M | 9.75%13.8M | -2.41%12.62M | 31.52%13.78M | 33.53%12.7M | 39.79%45.48M | 50.42%12.57M | 52.52%12.93M |
| Research and development costs | -18.14%35.59M | -11.08%36.37M | -0.61%163.52M | 3.94%36.17M | 9.97%42.99M | 3.28%43.47M | -15.75%40.9M | -5.51%164.52M | -28.91%34.8M | -16.82%39.09M |
| Operating profit | 16.95%-32.77M | -16.24%-34.89M | -10.79%-137.21M | -14.72%-31.03M | -12.82%-36.71M | -16.56%-39.45M | 1.30%-30.01M | -13.02%-123.84M | 19.80%-27.05M | 3.86%-32.54M |
| Net non-operating interest income expense | -32.17%1.25M | -13.70%857K | 294.91%6.21M | 139.78%1.51M | 375.57%1.87M | 620.39%1.84M | 993K | -22.17%1.57M | 631K | 393K |
| Non-operating interest income | 107.35%3.81M | 332.83%4.3M | 622.19%11.36M | 639.14%4.66M | 883.72%3.87M | 620.39%1.84M | --993K | -22.17%1.57M | --631K | --393K |
| Non-operating interest expense | --2.56M | --3.44M | --5.15M | --3.15M | --2M | --0 | --0 | --0 | --0 | --0 |
| Other net income (expense) | 407.41%83K | |||||||||
| Other non- operating income (expenses) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 407.41%83K | ---- | ---- |
| Income before tax | 16.20%-31.52M | -17.26%-34.03M | -7.21%-131M | -12.09%-29.52M | -8.39%-34.84M | -11.97%-37.61M | 3.75%-29.02M | -13.58%-122.19M | 21.14%-26.33M | 3.77%-32.15M |
| Income tax | -925.00%-363K | -1,729.41%-622K | 751.50%2.82M | -10,171.43%-1.41M | 1,044.30%4.22M | 44K | 5.56%-34K | 98.49%-433K | 100.16%14K | 95.24%-447K |
| Net income | 17.26%-31.16M | -15.25%-33.41M | -9.91%-133.82M | -6.68%-28.11M | -23.23%-39.07M | -12.10%-37.66M | 3.75%-28.99M | -54.13%-121.76M | -7.11%-26.35M | -31.95%-31.7M |
| Net income continuous Operations | 17.26%-31.16M | -15.25%-33.41M | -9.91%-133.82M | -6.68%-28.11M | -23.23%-39.07M | -12.10%-37.66M | 3.75%-28.99M | -54.13%-121.76M | -7.11%-26.35M | -31.95%-31.7M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 17.26%-31.16M | -15.25%-33.41M | -9.91%-133.82M | -6.68%-28.11M | -23.23%-39.07M | -12.10%-37.66M | 3.75%-28.99M | -54.13%-121.76M | -7.11%-26.35M | -31.95%-31.7M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 17.26%-31.16M | -15.25%-33.41M | -9.91%-133.82M | -6.68%-28.11M | -23.23%-39.07M | -12.10%-37.66M | 3.75%-28.99M | -54.13%-121.76M | -7.11%-26.35M | -31.95%-31.7M |
| Basic earnings per share | 17.88%-1.47 | -13.67%-1.58 | -7.95%-6.38 | -4.72%-1.33 | -21.57%-1.86 | -9.82%-1.79 | 6.08%-1.39 | -50.77%-5.91 | -4.10%-1.27 | -28.57%-1.53 |
| Diluted earnings per share | 17.88%-1.47 | -13.67%-1.58 | -7.95%-6.38 | -4.72%-1.33 | -21.57%-1.86 | -9.82%-1.79 | 6.08%-1.39 | -50.77%-5.91 | -4.10%-1.27 | -28.57%-1.53 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg